CERT1 and metabolic syndrome: Nevertheless, the main advantage of CERT1 in comparison to the diagnosis of metabolic syndrome, which is simply dichotomous (OB-MetS− or OB-MetS+), relies on the continuity of the biochemical variables (i.e., ceramides and ceramide ratios), components of CERT1, with the possibility of having cut-off values (quartiles) and of monitoring patient’s clinical state before and after any intervention, simply requiring a blood test at the lab (i.e., measurement of plasma levels of ceramides).